By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today announced a definitive agreement with Pronto Diagnostics to serve as the exclusive distributor of the OVA1 ovarian cancer test in Israel and the Palestinian territories.

Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.

Financial and other terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.